Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Alumkal JJ, et al. Among authors: xia z. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323. doi: 10.1073/pnas.1922207117. Epub 2020 May 18. Proc Natl Acad Sci U S A. 2020. PMID: 32424106 Free PMC article. Clinical Trial.
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. Nickols NG, et al. Among authors: xia z. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):531-538. doi: 10.1038/s41391-019-0134-5. Epub 2019 Feb 25. Prostate Cancer Prostatic Dis. 2019. PMID: 30804427 Free PMC article.
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team. Chen WS, et al. Among authors: xia z. Eur Urol. 2019 Nov;76(5):562-571. doi: 10.1016/j.eururo.2019.03.020. Epub 2019 Mar 28. Eur Urol. 2019. PMID: 30928160 Free PMC article.
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.
Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM, Alumkal JJ. Coleman DJ, et al. Among authors: xia z. Oncogene. 2019 Jul;38(28):5658-5669. doi: 10.1038/s41388-019-0815-5. Epub 2019 Apr 17. Oncogene. 2019. PMID: 30996246 Free PMC article.
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ. Coleman DJ, et al. Among authors: xia z. Neoplasia. 2020 Jun;22(6):253-262. doi: 10.1016/j.neo.2020.04.002. Epub 2020 May 11. Neoplasia. 2020. PMID: 32403054 Free PMC article.
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Guan X, et al. Among authors: xia z. Clin Cancer Res. 2020 Sep 1;26(17):4616-4624. doi: 10.1158/1078-0432.CCR-19-2303. Epub 2020 Jul 29. Clin Cancer Res. 2020. PMID: 32727885 Free PMC article.
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A 3rd, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. Kim DH, et al. Among authors: xia z. Clin Cancer Res. 2021 Sep 1;27(17):4923-4936. doi: 10.1158/1078-0432.CCR-20-4968. Epub 2021 Jun 18. Clin Cancer Res. 2021. PMID: 34145028 Free PMC article.
A Distinct Innate Immune Signature of Early Onset Colorectal Cancer.
Gardner IH, Siddharthan R, Watson K, Dewey E, Ruhl R, Khou S, Guan X, Xia Z, Tsikitis VL, Anand S. Gardner IH, et al. Among authors: xia z. Immunohorizons. 2021 Jun 23;5(6):489-499. doi: 10.4049/immunohorizons.2000092. Immunohorizons. 2021. PMID: 34162701 Free PMC article.
6,408 results